Table 2

Medication utilisation of the patients with acute coronary syndrome in the Arabian Gulf stratified by education status: findings from Gulf Coast registry

Characteristic, n (%) unless specified otherwiseAll
(N=3874)
EducatedP value
No (n=1835)Yes (n=2039)
Prior medications (N=2878)
 Aspirin2288 (80)1247 (83)1041 (76)<0.001
 Clopidogrel834 (29)451 (30)383 (28)0.212
 ACEIs1490 (52)833 (55)657 (48)<0.001
 ARBs557 (19)267 (18)290 (21)0.023
 Beta blockers1755 (61)935 (62)820 (60)0.172
 Statins2319 (81)1240 (82)1079 (79)0.008
 Other LLDs60 (2.1)14 (0.9)46 (3.4)<0.001
 Oral nitrates995 (35)633 (42)362 (26)<0.001
 CCBs578 (20)300 (20)278 (20)0.848
Discharged medications (N=3681)†
 Aspirin3559 (97)1682 (96)1877 (97)0.028
 Clopidogrel2698 (73)1146 (65)1552 (80)<0.001
 ACEIs2475 (67)1189 (68%)1286 (67)0.439
 ARBs558 (15)269 (15)289 (15)0.758
 Beta blockers3123 (85)1426 (81)1697 (88)<0.001
 Statins3568 (97)1699 (97)1869 (97)0.951
 Other LLDs87 (2.4)32 (1.8)55 (2.9)0.041
 Oral nitrates2212 (60)1197 (68)1015 (53)<0.001
 CCBs570 (15)289 (17)281 (15)0.108
 Dual antiplatelets3623 (98)1726 (99)1897 (98)0.670
 Five-drug regimen1922 (52)784 (45)1138 (59)<0.001
  • Percentages might not add up to 100% due to rounding off.

  • Dualantiplatelets, aspirin and clopidogrel concurrently; five drug regimen, concurrentprescribing of aspirin, clopidogrel, ACEI/ARB, statin, beta blocker.

  • *In the prior history, 996 patients had missing medications, while during †hospital discharge, 193 patients had missing medications.

  • ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; LLD, lipid lowering drug.